Enfermedad de Hodgkin

+ -Text Size

Otros recursos y referencias TEMAS

Referencias: guía detallada de la enfermedad de Hodgkin

Advani R. Optimal therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011. 2011;310−316.

American Cancer Society. Cancer Facts & Figures 2014. Atlanta, Ga: American Cancer Society; 2014.

Armitage JO. Early-stage Hodgkin’s lymphoma. New Engl J Med. 2010;363:653−662.

Clarke C, O’Malley C, Glaser S. Hodgkin lymphoma. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, 2007.

Connors, JM. State-of-the-art-therapeutics: Hodgkin’s lymphoma. J Clin Oncol. 2005;23:6400–6408.

Diehl V, Re D, Harris NL, Mauch PM. Hodgkin lymphoma. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2008:2167-2220.

Dores GM, Melayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin’s disease: A population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484–3494.

Horning SJ. Hodgkin’s lymphoma. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:2353-2369.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.

National Cancer Institute. Physician Data Query (PDQ). Adult Hodgkin Lymphoma Treatment. 2012. Accessed at www.cancer.gov/cancertopics/pdq/treatment/adulthodgkins/HealthProfessional on October 15, 2012.

National Cancer Institute. Physician Data Query (PDQ). Childhood Hodgkin Lymphoma Treatment. 2012. Accessed at www.cancer.gov/cancertopics/pdq/treatment/childhodgkins/HealthProfessional on October 15, 2012.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Hodgkin Lymphoma. Version 2,2012. Accessed at www.nccn.org/professionals/physician_gls/PDF/hodgkins.pdf on October 15, 2012.

Ramchandren R. Advances in the treatment of relapsed or refractory Hodgkin’s lymphoma. Oncologist. 2012;17:367−376.

Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr. 2009;52:611−622.

Yahalom J, Straus D. Hodgkin lymphoma. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, eds. Cancer Management: A Multidisciplinary Approach. 13th ed. Lawrence, KS: UBM Medica; 2010:715−738.

Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363:1812−1821.

Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: Results of a phase II study. J Clin Oncol. 2012;30:2197−2203.


Fecha de última actualización: 03/05/2013
Fecha de último cambio o revisión: 02/10/2014